Northwire Canada EditionFriday, July 10, 2026
Sign inSubscribe
Northwire
⌕
S 0.165 +37.5% NNX 0.035 +0.0% ABX 52.05 −0.3% TTS 2.40 −4.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 23.32 +12.1% TUNG 1.73 +2.4% LGO 1.00 −3.4% EMM 0.080 +0.0% OGN 3.45 +2.1% MSA 6.50 +1.1% SGZ 0.040 −11.1% GRSL 0.307 −3.9% DEX 0.380 −1.3% WMS 0.040 +0.0% S 0.165 +37.5% NNX 0.035 +0.0% ABX 52.05 −0.3% TTS 2.40 −4.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 23.32 +12.1% TUNG 1.73 +2.4% LGO 1.00 −3.4% EMM 0.080 +0.0% OGN 3.45 +2.1% MSA 6.50 +1.1% SGZ 0.040 −11.1% GRSL 0.307 −3.9% DEX 0.380 −1.3% WMS 0.040 +0.0%
Earnings Neutral

Light AI reports Financial Results for Three Months ended March 31, 2026

Pre-revenue diagnostics firm narrows losses but liquidity runway tightens ahead of commercial launch

By The Northwire Desk — AI Analysis May 15, 2026 · 18:58 ALGO · 0.19 LIGHT AI INC.
Executive Summary
  • Light AI reported Q1 2026 financial results showing a net comprehensive loss of $2,062,424, an improvement from the $2.25 million loss in Q4 2025.
  • Cash position decreased to $4.6 million as of March 31, 2026, down from $6.5 million at year-end 2025.
  • Net working capital dropped significantly to approximately $3.7 million from $5.4 million in December 2025.
  • Commercialization for the QuickScan™ Strep A software is now planned for mid-2026, slightly accelerated from previous Q3-Q4 expectations.
  • R&D expenses decreased 40% year-over-year but increased 24% quarter-over-quarter due to recruiting costs in G&A.
  • Cash used in operating activities was $1.9 million during Q1 2026, down from $5.2 million in the prior year period.
Material Impact
  • The earnings release is not a material game changer as it does not introduce new financing or revenue streams.
  • Progress on commercialization timeline (mid-2026) is positive but incremental and expected by the market given previous guidance.
  • Liquidity metrics show deterioration; working capital decreased by $1.7 million in one quarter, raising concerns about runway sufficiency before revenue generation begins.
  • The slight improvement in net loss is routine for a pre-revenue company transitioning to commercialization and does not materially alter risk profile without confirmed sales.
  • No new strategic investors or major contracts were announced that would validate the business model beyond internal milestones.
ALGO · Price
Company Overview
  • Light AI Inc. develops an AI-powered diagnostic software platform for medical conditions using smartphone imaging.
  • Flagship product: QuickScan™ Strep A application, which detects Group A Streptococcus from smartphone images without swabs or lab tests.
  • Platform claims 96.57% overall accuracy and 100% Negative Predictive Value for distinguishing viral vs. bacterial pharyngitis (pre-FDA validation).
  • Strategic vision includes a cloud-based "Digital Clinical Lab" to reduce reliance on traditional lab infrastructure.
  • Company is transitioning from R&D phase to commercialization with Version 1.0 software completed in November 2025.
Read the original news release →

More from LIGHT AI INC.

Jun 29, 2026 · 07:00

Pre-revenue AI diagnostics developer advances regulatory clearance for smartphone-based Strep A detection amid persistent cash burn and dilution risk.

Production / Operations Jun 22, 2026 · 18:41

Pre-revenue AI diagnostics company closes dilutive financing to fund regulatory milestones amid going concern risks.

Financings Jun 19, 2026 · 18:00

Light AI Announces Closing of C$5,000,000 Secured Convertible Debenture Unit Financing

Financings Jun 15, 2026 · 18:25

Light AI pilots Strep A diagnostic in NZ as FDA pivotal trial launches, but pre-revenue status and going concern risk persist.

Production / Operations Jun 04, 2026 · 07:00

Light AI Advances FDA Pivotal Trial for Strep A AI Diagnostic Amid Cash Burn and Dilutive Financing

Regulatory May 21, 2026 · 07:15

Light AI’s C$5 Million Lifeline Comes With Dilutive Terms and Board Strings as Cash Burn Intensifies

Financings